NeuroVive Pharmaceutical


SEK234.3m market cap

SEK1.26 last close

NeuroVive Pharmaceutical is a Swedish biopharmaceutical company with deep expertise in mitochondrial medicine. It has a diversified portfolio in terms of indications and employs a dual strategy: it develops a core portfolio of assets for orphan diseases and seeks to out-license proprietary products for non-orphan indications.

Investment summary

NeuroVive Pharmaceutical is a mitochondrial medicine specialist. The company’s core portfolio targets orphan indications: traumatic brain injury (TBI) with NeuroSTAT, various genetic mitochondrial diseases with KL1333 and NVP015, and mitochondrial myopathy with NVP025. NeuroVive’s IND for clinical development of NeuroSTAT in TBI has been approved by the FDA and preparations for the Phase IIb proof-of-concept study are ongoing. The second most advanced product KL1333, in-licensed from Yungjin Pharm in May 2017, demonstrated positive results in the Phase I trial in South Korea and NeuroVive initiated a Phase Ia/b study in March 2019. So far in 2019, NeuroVive has raised SEK108m net and licensed two research compounds from NVP015 programme to Oroboros.

Y/E Dec
Revenue (SEKm)
EPS (fd) (öre)
P/E (x)
P/CF (x)
2017A 0.6 (67.9) (70.1) (149.31) N/A N/A
2018A 2.5 (66.7) (68.8) (94.07) N/A N/A
2019E 1.5 (91.8) (92.0) (63.56) N/A N/A
2020E 1.5 (114.9) (115.0) (64.60) N/A N/A
Industry outlook

NeuroVive has a diversified portfolio with all assets aimed at improving mitochondrial metabolism and function. We feel this puts NeuroVive among the very few experts in mitochondrial medicine.

Last updated on 23/07/2019
Share price graph
Balance sheet
Forecast net cash (SEKm) 42.1
Forecast gearing ratio (%) N/A
Price performance
Actual 4.0 (6.0) (74.2)
Relative* 2.9 (4.7) (75.3)
52-week high/low SEK4.9/SEK1.2
*% relative to local index
Key management
Mark Farmery Chairman
Erik Kinnman CEO
Catharina Jz Johansson CFO
Eskil Elmér Chief Scientist Officer
Magnus Hansson Chief Medical Officer